A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
An early phase study to compare the safety and tolerability of different dose schedules of SC administered dengue vaccine in healthy adults and to compare the immunogenicity of different dose schedules of the vaccine
Blood samples will be obtained for safety labs on Days 0, 7, 14, 90, 97 and 104 and measurement of viremia at baseline (during the screening period or on Day 0), and then on Days 7, 9, 11, 14, 17, 21, 90, 97, and 104. Blood samples for measurement of dengue neutralizing antibodies in serum will be obtained at baseline (during the screening period or on Day 0), then on Days 30, 90 and 120.
The entire duration for each individual subject's participation will be approximately 5 months including recruitment and collection of data for primary outcomes (through Day 120).
| Condition | Intervention | Phase |
|---|---|---|
|
Healthy |
Biological: DENVax |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Prevention |
| Official Title: | A Randomized, Phase 1b Study to Investigate the Safety and Immunogenicity of Various Schedules of Tetravalent Chimeric Dengue Vaccine in Healthy Adult Volunteers Between the Ages of 18 - 45 Years |
- Frequency and severity of adverse events, including local and systemic reactions [ Time Frame: various timepoints up to 30 days after each dose ] [ Designated as safety issue: Yes ]outcome measures include evaluations of local and systemic reactogenicity and adverse events (all subjects) and measurement of routine hematology and chemistry parameters
- Immunogenicity [ Time Frame: various timepoints up to 30 days after each dose ] [ Designated as safety issue: Yes ]Immunogenicity will be assessed using Neutralizing antibody titers against each of the four dengue serotypes
| Estimated Enrollment: | 152 |
| Study Start Date: | February 2012 |
| Estimated Primary Completion Date: | May 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Group 1 |
Biological: DENVax
DENVax given subcutaneously at Day 0 and 90
|
| Experimental: Group 2 |
Biological: DENVax
DENVax given subcutaneously at Day 0 and 90
|
| Experimental: Group 3 |
Biological: DENVax
DENVax given subcutaneously at Day 0 and 90
|
|
Experimental: group 4
DENVax new formulation
|
Biological: DENVax
DENVax given subcutaneously at Day 0 and 90
|
|
Experimental: Group 5
DENVax current formulation
|
Biological: DENVax
DENVax given subcutaneously at Day 0 and 90
|
|
Experimental: Group 6
DENVax new formulation
|
Biological: DENVax
DENVax given subcutaneously at Day 0 and 90
|
|
Experimental: Group 7
DENVax current formulation
|
Biological: DENVax
DENVax given subcutaneously at Day 0 and 90
|
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Male or female at least 18 years and ≤ 45 years old at time of screening
- In good health as determined by medical history, physical examination including height and weight
- Normal clinical safety laboratory examinations (Na, K, Glucose, BUN, creatinine, ALT, AST, total bilirubin, WBC, neutrophil count, hemoglobin, platelets, PT, PTT, and urinalysis (by dipstick)).
- Weight: Body Mass Index (BMI) ≤32
- Blood tests negative for antibodies to HIV-1, Hepatitis C, and Hepatitis B surface antigen
Exclusion Criteria:
- Any condition which would limit the subject's ability to complete the study in the opinion of the Investigator
- Clinically significant ECG findings
- History of any significant dermatologic disease in the last 6 months,
- History of diabetes mellitus
- History of recurring headaches or migraines (more frequent than once per week) or on prescription medication for treatment of recurring headaches or migraines
- Hypersensitivity to any vaccine
- Receipt of any vaccine in the 4 weeks preceding the first vaccination
- Planned receipt of any vaccine in the 4 weeks following each of the vaccinations in this study
- Known history of Japanese Encephalitis Virus (JEV) and/or Yellow Fever (YF)
- Previous vaccination (in a clinical trial or with an approved product) against flaviviruses including dengue, yellow fever (YF) and Japanese Encephalitis (JE)
- Seropositivity to dengue or West Nile (WN) virus
- Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months
- Use within the previous 6 months of systemic corticosteroids therapy (at a dose of at least 0.5 mg/kg/day). Topical prednisone is not permitted if currently in use or within the last 3 months. Note, inhaled prednisone (or equivalent) is allowed
- Use of any non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen or antihistamines for the 3 days immediately prior to each vaccination
- Use of any prescription or over the counter medications (besides those specifically mentioned above or those required for medical management of concurrent diseases) 7 days before the first vaccination (Day 0)
- Positive urine screen for cocaine, amphetamines, opiates, or cannabinoids
- Donation of blood 6 weeks before the first dose(s) (Day 0) until 30 days after the dose on day 90
- Females who are pregnant or lactating
Contacts and Locations| Contact: Michele Hurliman | 970-692-5515 | mhurliman@inviragen.com |
| United States, Colorado | |
| Poudre Valley Health System | Completed |
| Fort Collins, Colorado, United States | |
| United States, Texas | |
| Univ of Texas Medical Branch | Active, not recruiting |
| Galveston, Texas, United States | |
| United States, Utah | |
| Advanced Clinical Research | Recruiting |
| Salt Lake City, Utah, United States, 84088 | |
| Contact: Julie Neff 801-542-8190 ext 119 jneff@acr-research.com | |
| Study Director: | Gilad Gordon, MD | Inviragen Inc. |
More Information
No publications provided
| Responsible Party: | Inviragen Inc. |
| ClinicalTrials.gov Identifier: | NCT01542632 History of Changes |
| Other Study ID Numbers: | INV-DEN-104 |
| Study First Received: | February 27, 2012 |
| Last Updated: | March 26, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Inviragen Inc.:
|
safety and immunogenicity of dengue vaccine |
Additional relevant MeSH terms:
|
Dengue Arbovirus Infections Virus Diseases Flavivirus Infections |
Flaviviridae Infections RNA Virus Infections Hemorrhagic Fevers, Viral |
ClinicalTrials.gov processed this record on May 22, 2013